▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

David Liang

Pfoolishly

Recent Articles by David Liang

money and pills on scale

Jun 23, 2017 by David Liang

AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know

Could the world's best-selling drug have a protégé?

money and pills on scale

Jun 14, 2017 by David Liang

Amicus Therapeutics: Is This Biotech an Orphan Underdog?

After months of crazy volatility, the stock seems to have made up its mind on which direction to go: up

hand drawing chart stock return

Jun 13, 2017 by David Liang

Celgene's Next Blockbuster: What You Need to Know

Could Celgene's newest drug finally get this company the respect it deserves?

hand drawing chart stock return

Jun 7, 2017 by David Liang

Omeros: Can the Growth Story Continue?

After a 60% increase since the start of 2017, can shares continue to move higher?

jenga tower risk

Jun 5, 2017 by David Liang

Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?

Does Zogenix stand a chance against the cannabis king?

money and pills on scale

May 29, 2017 by David Liang

With Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory?

Shares of Synergy are down, but things are looking up for this GI gem

money and pills on scale

May 28, 2017 by David Liang

Two Red Hot Biotechs With Big Near-term Catalysts Ahead

June will be a pivotal month for shareholders of Portola Pharmaceuticals and Neos Therapeutics

money and pills on scale

Jun 1, 2017 by David Liang

Could This Tiny Biotech Be the David to Mylan's EpiPen Goliath?

Adamis is working on an EpiPen alternative, and the payoff could be huge

jenga tower risk

Apr 25, 2017 by David Liang

Biogen and Alzheimer’s: There’s a Fundamental Problem Here

Biogen's "moonshot" will likely end in failure

money and pills on scale

Apr 25, 2017 by David Liang

Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market

After a significant pullback in April, is now the right time to jump into Acadia?

GettyImages-547513542

Apr 18, 2017 by David Liang

Axovant: A New CEO Doesn't Change Anything

A hedge fund founder and a once-failed drug are a recipe for disaster

money and pills on scale

Apr 17, 2017 by David Liang

Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017

A combination one-two punch has left investors cheering

the-strategy-1080527_1920

Apr 12, 2017 by David Liang

Amgen's Offering a Money Back Guarantee for Repatha. Will It Be Enough?

After a slow start, are sales of Repatha finally about to pick up?

the-strategy-1080527_1920

Apr 7, 2017 by David Liang

Sanofi Buying Flexion: A Smart Move?

Will Sanofi acquire anything? Or is this deal smarter than it seems?

debt past due notice

Apr 3, 2017 by David Liang

Bill Ackman Just Gave Up on Valeant. Should You Too?

What lessons should investors learn from Ackman's greatest mistake?

hand drawing chart stock return

Mar 31, 2017 by David Liang

Aurinia Pharmaceuticals: Where to From Here?

After dropping more than 30% off its highs, is now the time to buy this baby biotech?

jenga tower risk

Mar 28, 2017 by David Liang

Battle in the Boardroom: What's Next for Immunomedics

Will VenBio successfully negotiate a higher bid for IMMU-132?

jenga tower risk

Mar 28, 2017 by David Liang

Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017

Will shares move higher? Or will a boardroom battle leave this biotech cruising for a bruising?

man holding money hundred bills

Mar 24, 2017 by David Liang

After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?

Beneath the surface, Rigel has been gearing up for an explosive 2017

hand drawing chart stock return

Mar 24, 2017 by David Liang

Omeros: Power in the Pipeline

This tiny biotech could be Alexion's worst nightmare

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services